- Recurrent herpes labialis: developing drugs for treatment and prevention1
- Redesigning practice to improve care delivery: site visit report1
- Reducing Medicare’s payment rates for intermittent urinary catheters can save the program and beneficiaries millions of dollars each year1
- Reducing microbial food safety hazards in the production of seed for sprouting: guidance for industry1
- Reducing the risk: final impact report1
- Reducing the risk: impact findings from the teen pregnancy prevention replication study : research brief1
- Reductions in deaths and hospitalizations associated with COVID-19 vaccinations among Medicare beneficiaries: full year 2021 estimates2
- Referencing approved drug products in ANDA submissions2
- Referencing the definition of “device” in the Federal Food, Drug, and Cosmetic Act in guidance, regulatory documents, communications, and other public documents: guidance for industry and Food and Drug Administration staff1
- Reformulating drug products that contain carbomers manufactured with benzene: guidance for industry1
- Refusal of inspection by a foreign food establishment or foreign government: guidance for industry1
- Refuse to accept policy for 510(k)s: guidance for industry and Food and Drug Administration staff1
- Regenerative medicine and advanced therapies: information on workforce and education : report to congressional committees1
- Regenerative medicine. Therapeutic applications, challenges, and policy options1
- Registered apprenticeships: a viable career path for the early childhood workforce1
- Registration and listing of cosmetic product facilities and products: guidance for industry1
- Registration and product listing for owners and operators of domestic tobacco product establishments: (revised)1
- Regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps): small entity compliance guide : guidance for industry1
- Regulatory classification of pharmaceutical co-crystals1
- Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use : guidance for industry and Food and Drug Administration staff1